Castle Biosciences, Inc.(CSTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CSTL Castle Biosciences, Inc.

Trading 12-22 14:38:51 EST

41.84

+2.40

+6.09%

High42.18	Low39.89	Vol306.04K
Open40.00	D1 Closing39.44	Amplitude5.79%
Mkt Cap1.22B	Tradable Cap1.12B	Total Shares29.19M
T/O12.67M	T/O Rate1.15%	Tradable Shares26.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":41.84,"timestamp":1766432314292,"preClose":39.44,"halted":0,"volume":306039,"delay":0,"floatShares":26724873,"shares":29188659,"eps":-0.434162,"marketStatus":"Trading","change":2.4,"latestTime":"12-22 14:38:51 EST","open":40,"high":42.175,"low":39.89,"amount":12666450.775844999,"amplitude":0.057936,"askPrice":41.94,"askSize":20,"bidPrice":41.83,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-0.434162,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":39.44,"preHourTrading":{"tag":"盘前","latestPrice":40.24,"preClose":39.44,"latestTime":"09:29 EST","volume":485,"amount":19397.620590000002,"timestamp":1766413755172},"postHourTrading":{"tag":"盘后","latestPrice":38.66,"preClose":39.44,"latestTime":"19:34 EST","volume":45587,"amount":1797602.195,"timestamp":1766190899607},"volumeRatio":1.155192,"impliedVol":0.6136,"impliedVolPercentile":0.628},"requestUrl":"/m/hq/s/CSTL","defaultTab":"news","newsList":[{"id":"2593487442","title":"Castle Biosciences Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487442?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:58","pubTimestamp":1766408280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CSTL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 07:58 ET (12:58 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2592447197","title":"Castle Biosciences COO Kristen M. Oelschlager Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592447197","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592447197?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:07","pubTimestamp":1766178422,"startTime":"0","endTime":"0","summary":"Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences Inc., reported a disposal of common shares of Castle Biosciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL86kYDz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Castle Biosciences COO Kristen M. Oelschlager Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2592697721","title":"BRIEF-Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2592697721","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592697721?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:05","pubTimestamp":1766145925,"startTime":"0","endTime":"0","summary":"BRIEF-Castle Biosciences Reports Inducement Grants Under Nasdaq Listing RuleDec 19 (Reuters) - Castle Biosciences Inc CSTL.O:CASTLE BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA6WJ7QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2592169408","title":"Castle Biosciences Grants RSUs to 83 New Employees under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2592169408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592169408?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:00","pubTimestamp":1766145610,"startTime":"0","endTime":"0","summary":"Castle Biosciences Inc. has granted restricted stock units  to 83 employees, covering a total of 139,494 shares of common stock. The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in three equal annual installments, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLCFfqV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4196","LU2210150020.SGD","SG9999014021.USD","BK4112","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","CSTL","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","SG9999014005.SGD"],"gpt_icon":0},{"id":"2592169109","title":"Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592169109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592169109?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:00","pubTimestamp":1766145600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA6WJ7QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2592437949","title":"Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592437949","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592437949?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:20","pubTimestamp":1766006437,"startTime":"0","endTime":"0","summary":"Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9Vg2wK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2592940009","title":"Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592940009","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592940009?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972814,"startTime":"0","endTime":"0","summary":"Castle Biosciences Inc. announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing -based gene mutation analysis with the combination of DecisionDx-UM and PRAME gene expression for predicting outcomes in patients with uveal melanoma . The study, titled \"Early Genetic Evolution of Driver Mutations in Uveal Melanoma,\" was conducted by the Collaborative Ocular Oncology Group  and has been published in Nature Communications. Results showed that the combination of DecisionDx-UM and PRAME outperformed gene mutation analysis in predicting metastasis-free survival and overall survival in UM patients. The study authors attribute the improved performance to the ability of DecisionDx-UM to measure gene activity from both tumor and surrounding immune cells, providing a comprehensive assessment of the tumor microenvironment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5qzbNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","LU0314104364.USD","NDAQ","BK4588","BK4112","CSTL","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","LU2095319765.USD","BK4196"],"gpt_icon":0},{"id":"2591827309","title":"Should Expert Endorsement of DecisionDx-Melanoma’s Prognostic Value Require Action From Castle Biosciences (CSTL) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591827309","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591827309?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:17","pubTimestamp":1765891023,"startTime":"0","endTime":"0","summary":"Earlier this month, Castle Biosciences announced that an independent expert consensus panel published a paper endorsing its DecisionDx-Melanoma test as a clinically validated tool that adds prognostic value beyond standard staging in cutaneous melanoma care.\nThe panel’s unanimous agreement, based on 26 studies covering more than 7,500 patients, positions DecisionDx-Melanoma as part of best-practice risk stratification and treatment planning, while separate meta-analysis data support...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/should-expert-endorsement-of-decisiondx-melanomas-prognostic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/should-expert-endorsement-of-decisiondx-melanomas-prognostic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4196","CSTL","BK4211"],"gpt_icon":0},{"id":"2591621008","title":"Castle Biosciences CFO Frank Stokes Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591621008","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591621008?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:09","pubTimestamp":1765832978,"startTime":"0","endTime":"0","summary":"Frank Stokes, Chief Financial Officer of Castle Biosciences Inc., reported a disposal of common shares of Castle Biosciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2rH4zx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Castle Biosciences CFO Frank Stokes Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2590506104","title":"Castle Biosciences Inc : Btig Raises Target Price to $50 From $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590506104?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:43","pubTimestamp":1765543402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI0UE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2590505688","title":"Castle Biosciences Study Confirms TissueCypher Outperforms Traditional Methods in Predicting Esophageal Cancer Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505688","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505688?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:00","pubTimestamp":1765540823,"startTime":"0","endTime":"0","summary":"Castle Biosciences Inc. has announced the publication of a new systematic review and meta-analysis evaluating the TissueCypher Barrett's Esophagus test. The results, published in the Journal of Clinical Gastroenterology, consolidate data from six previously published studies and indicate that TissueCypher provides clinically validated risk stratification for patients with Barrett's esophagus. The analysis found that TissueCypher outperforms traditional pathology or clinical factors alone in identifying patients at increased risk of developing esophageal cancer. Patients with high or intermediate-risk results showed annual progression rates above guideline-based thresholds for intensified care. These findings have already been published and are intended to support personalized, risk-aligned patient management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL6pKZxr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014013.SGD","CSTL","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00BKPKM429.USD","BK4112","SG9999014021.USD","SG9999014039.USD","BK4196","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0},{"id":"2590505371","title":"Systematic Review and Meta-Analysis Confirms Tissuecypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505371?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:00","pubTimestamp":1765540800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA49KRRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2590224508","title":"Castle Biosciences Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590224508","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590224508?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:17","pubTimestamp":1765538220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CSTL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 06:17 ET (11:17 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2590414343","title":"Castle Biosciences’ DecisionDx-Melanoma Endorsed as Best-Practice Tool by Expert Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2590414343","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590414343?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:01","pubTimestamp":1765281671,"startTime":"0","endTime":"0","summary":"Castle Biosciences Inc. announced the publication of an independent expert consensus paper endorsing its DecisionDx-Melanoma test as a best-practice tool for managing patients with cutaneous melanoma. The expert panel, consisting of ten melanoma specialists from academic and clinical institutions, reviewed 26 published studies involving more than 7,500 patients. The panel concluded that DecisionDx-Melanoma provides prognostic information independent of traditional clinicopathologic factors and can enhance risk assessment and clinical decision-making when integrated with existing staging systems. The consensus results are already available and were published in the expert panel paper.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLb0jl8h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4196","SG9999014021.USD","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","NDAQ","BK4112","IE00B3QW5Z07.USD","SG9999014005.SGD","CSTL"],"gpt_icon":0},{"id":"2590668493","title":"Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590668493","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590668493?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:29","pubTimestamp":1765229373,"startTime":"0","endTime":"0","summary":"Derek J. Maetzold, President & Chief Executive Officer of Castle Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9C4m67:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2588470804","title":"Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588470804","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588470804?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:09","pubTimestamp":1764623385,"startTime":"0","endTime":"0","summary":"Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences Inc., reported a disposal of common shares of Castle Biosciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL8j4CSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2586826758","title":"Castle Biosciences CEO Derek J. Maetzold Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586826758","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586826758?lang=en_us&edition=fundamental","pubTime":"2025-11-27 03:59","pubTimestamp":1764187169,"startTime":"0","endTime":"0","summary":"Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences Inc., reported a disposal of common shares of Castle Biosciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5HRlzl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Castle Biosciences CEO Derek J. Maetzold Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2586490725","title":"Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586490725","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586490725?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:24","pubTimestamp":1764019484,"startTime":"0","endTime":"0","summary":"Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8mpg1h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2585226281","title":"Castle Biosciences (CSTL): Evaluating Valuation After New Data on DecisionDx-Melanoma Diagnostic Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2585226281","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585226281?lang=en_us&edition=fundamental","pubTime":"2025-11-22 07:39","pubTimestamp":1763768344,"startTime":"0","endTime":"0","summary":"Castle Biosciences (CSTL) just released new data on its DecisionDx-Melanoma test, showing it can refine how sentinel lymph node biopsies are decided for melanoma patients and help predict recurrence risk more accurately.\nSee our latest analysis for Castle Biosciences.\nThe latest data release and ongoing recognition as a Top Workplace have kept momentum building for Castle Biosciences, fueling a 52.7% 1-month share price return and drawing fresh attention to its long-term potential. Investors...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/castle-biosciences-cstl-evaluating-valuation-after-new-data","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/castle-biosciences-cstl-evaluating-valuation-after-new-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSTL","BK4196","DCF"],"gpt_icon":0},{"id":"2584176929","title":"Scibase And Castle Biosciences Expand Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2584176929","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584176929?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:04","pubTimestamp":1763571850,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - SciBase Holding AB (publ) ::*SCIBASE AND CASTLE BIOSCIENCES EXPAND COLLABORATION AND LICENSE AGREEMENT AND ENTER INTO LOAN AGREEMENT OF SEK 20 MILLION*SCIBASE AND CASTLE BIOSCIENCES ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1C823z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.castlebiosciences.com","stockEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":0.1382},{"period":"3month","weight":0.6157},{"period":"6month","weight":1.1296},{"period":"1year","weight":0.4559},{"period":"ytd","weight":0.4799}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.030345},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.068437},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.002672},{"month":4,"riseRate":0.5,"avgChangeRate":-0.084405},{"month":5,"riseRate":0.5,"avgChangeRate":0.014411},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.00564},{"month":7,"riseRate":0.666667,"avgChangeRate":0.055356},{"month":8,"riseRate":1,"avgChangeRate":0.247828},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.100564},{"month":10,"riseRate":0.428571,"avgChangeRate":0.054309},{"month":11,"riseRate":0.571429,"avgChangeRate":0.067915},{"month":12,"riseRate":0.571429,"avgChangeRate":0.095744}],"exchange":"NASDAQ","name":"Castle Biosciences, Inc.","nameEN":"Castle Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Castle Biosciences, Inc.(CSTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Castle Biosciences, Inc.(CSTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Castle Biosciences, Inc.,CSTL,Castle Biosciences, Inc.股票,Castle Biosciences, Inc.股票老虎,Castle Biosciences, Inc.股票老虎国际,Castle Biosciences, Inc.行情,Castle Biosciences, Inc.股票行情,Castle Biosciences, Inc.股价,Castle Biosciences, Inc.股市,Castle Biosciences, Inc.股票价格,Castle Biosciences, Inc.股票交易,Castle Biosciences, Inc.股票购买,Castle Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Castle Biosciences, Inc.(CSTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Castle Biosciences, Inc.(CSTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}